iBio, Inc. (IBIO): Price and Financial Metrics

iBio, Inc. (IBIO): $0.29

0.01 (+3.65%)

POWR Rating

Component Grades








Add IBIO to Watchlist
Sign Up

Industry: Biotech




#358 of 390

in industry

IBIO Price/Volume Stats

Current price $0.29 52-week high $2.60
Prev. close $0.28 52-week low $0.25
Day low $0.28 Volume 342,600
Day high $0.31 Avg. volume 1,328,816
50-day MA $0.30 Dividend yield N/A
200-day MA $0.78 Market Cap 8.15M

IBIO Stock Price Chart Interactive Chart >


  • Growth is the dimension where IBIO ranks best; there it ranks ahead of 90.63% of US stocks.
  • IBIO's strongest trending metric is Growth; it's been moving up over the last 132 days.
  • IBIO's current lowest rank is in the Quality metric (where it is better than 1.83% of US stocks).

IBIO Stock Summary

  • IBIO has a market capitalization of $5,207,384 -- more than approximately merely 2.92% of US stocks.
  • With a price/sales ratio of 85.37, IBIO INC has a higher such ratio than 97.64% of stocks in our set.
  • Revenue growth over the past 12 months for IBIO INC comes in at -97.83%, a number that bests merely 0.86% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to IBIO, based on their financial statements, market capitalization, and price volatility, are SERA, BNGO, NSTG, HLGN, and LAW.
  • Visit IBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.ibioinc.com.

IBIO Valuation Summary

  • In comparison to the median Healthcare stock, IBIO's price/sales ratio is 4384.21% higher, now standing at 85.2.
  • Over the past 169 months, IBIO's price/sales ratio has gone up 52.3.

Below are key valuation metrics over time for IBIO.

Stock Date P/S P/B P/E EV/EBIT
IBIO 2023-09-22 85.2 0.3 -0.1 -0.2
IBIO 2023-09-21 90.2 0.3 -0.1 -0.2
IBIO 2023-09-20 91.8 0.3 -0.1 -0.2
IBIO 2023-09-19 90.2 0.3 -0.1 -0.2
IBIO 2023-09-18 93.4 0.3 -0.1 -0.2
IBIO 2023-09-15 93.4 0.3 -0.1 -0.2

IBIO Growth Metrics

    Its 2 year revenue growth rate is now at 114.24%.
  • The 4 year cash and equivalents growth rate now stands at -19.18%.
  • Its 2 year cash and equivalents growth rate is now at 295.5%.
Over the past 33 months, IBIO's revenue has gone up $428,000.

The table below shows IBIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2.172 -42.092 -59.516
2022-06-30 2.383 -37.48 -50.391
2022-03-31 2.813 -33.203 -33.286
2021-12-31 1.635 -34.608 -28.621
2021-09-30 2.172 -32.341 -24.873
2021-06-30 2.371 -30.064 -23.467

IBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IBIO has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
  • IBIO's asset turnover comes in at 0.017 -- ranking 375th of 681 Pharmaceutical Products stocks.
  • COLL, COCP, and IRWD are the stocks whose asset turnover ratios are most correlated with IBIO.

The table below shows IBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 0.383 -0.256
2021-03-31 0.024 0.836 -0.331
2020-12-31 0.023 1.000 -0.317
2020-09-30 0.027 1.000 -0.273
2020-06-30 0.032 1.000 -0.231
2020-03-31 0.036 1.000 -0.271

iBio, Inc. (IBIO) Company Bio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.

IBIO Latest News Stream

Event/Time News Detail
Loading, please wait...

IBIO Latest Social Stream

Loading social stream, please wait...

View Full IBIO Social Stream

Latest IBIO News From Around the Web

Below are the latest news stories about IBIO INC that investors may wish to consider to help them evaluate IBIO as an investment opportunity.

iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics

- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas and SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matt Greving Ph.D., its Vice President of Platform Technologies and Machine Learning, has been selected to present on the Co

Yahoo | October 10, 2023

iBio Explains Recent Filing of Registration Statement

– No new securities are being registered under the Post-Effective Amendment –BRYAN, Texas and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- In response to investor inquiries received about the post-effective amendment to its Form S-3 on Form S-1 (the “Post-Effective Amendment”) filed on Friday, September 29, 2023 with the United States Securities and Exchange Commission (“SEC”), iBio Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today p

Yahoo | October 2, 2023

Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done

The healthcare industry has historically provided good returns to investors, however there are also healthcare stocks you will want to sell.

Tomas Levani on InvestorPlace | September 28, 2023

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the fiscal year ended June 30, 2023. Revenues for the fiscal year ended June 30, 2023 were $nil, compared to $1.9 million in fiscal 2022. Total operating expenses, not including the loss from d

Yahoo | September 27, 2023

iBio Announces Amendment to Credit Agreement with Woodforest

– Extends maturity date to December 31, 2023 –– Allows time to close pending sale of CDMO facility –BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and Woodforest National Bank (“Woodforest”) have entered into a sixth amendment (the “Amendment”) to their November 1, 2021 credit agreement (the “Credit Agreement”

Yahoo | September 21, 2023

Read More 'IBIO' Stories Here

IBIO Price Returns

1-mo -0.17%
3-mo -6.42%
6-mo -60.27%
1-year -80.54%
3-year -99.23%
5-year -98.55%
YTD -34.74%
2022 -96.76%
2021 -47.71%
2020 321.69%
2019 -66.80%
2018 -57.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!